# Mixed Invasive Adenoid Cystic and Lobular Carcinoma of the Breast: A Case Report of a Rare Hybrid Tumor

**Authors:** Maha S Babker, Hector Chavarria

PMC · DOI: 10.7759/cureus.101902 · Cureus · 2026-01-20

## TL;DR

A rare case of breast cancer combining two distinct types, adenoid cystic and lobular carcinoma, highlights the need for precise diagnosis and tailored treatment.

## Contribution

First documented case of a hybrid breast tumor composed of adenoid cystic and lobular carcinoma.

## Key findings

- The tumor exhibited both triple-negative adenoid cystic and hormone receptor-positive lobular components.
- Sentinel lymph nodes showed no metastasis despite the aggressive Ki-67 index in the lobular component.
- The case emphasizes the importance of integrating histomorphology and immunohistochemistry for accurate diagnosis.

## Abstract

Adenoid cystic carcinoma (ACC) of the breast is an exceedingly rare subtype of triple-negative breast cancer, accounting for less than 0.1% of all breast malignancies. In contrast, invasive lobular carcinoma (ILC) is a more common special histologic type, comprising 5-15% of breast cancers and typically characterized by estrogen receptor positivity and complete loss of epithelial cadherin (E-cadherin) expression. The coexistence of these two biologically and morphologically distinct neoplasms within the same breast lesion is exceptionally rare and, to our knowledge, has not been previously documented.

A 62-year-old Caucasian female patient presented with nonspecific stinging discomfort in the right breast. Diagnostic imaging revealed a 1.8 cm irregular, spiculated mass. A core needle biopsy demonstrated invasive mammary carcinoma that was estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative. Following right breast mastectomy and sentinel lymph node biopsy, final pathology revealed a biphasic neoplasm composed of both ACC and lobular carcinoma (LC) components. The ACC component exhibited classic cribriform and tubular architecture, a triple-negative immunophenotype, strong transformation-related protein 63 (p63) and cluster of differentiation 117 (CD117; c-Kit) positivity, and a low Ki-67 proliferation index (9.8%). The LC component lacked a classic single-file growth pattern but showed dyscohesive cell clusters with complete loss of E-cadherin expression, strong estrogen receptor positivity (94.18%), and a markedly elevated Ki-67 index (42.9%). All seven sentinel lymph nodes were negative for metastatic carcinoma.

This rare case of synchronous ACC and ILC underscores the diagnostic complexity of composite breast tumors. Accurate classification requires careful correlation of histomorphology with immunohistochemical findings, particularly when one or both components exhibit non-classical architectural patterns. Given the contrasting biological behavior of triple-negative ACC and hormone receptor-positive ILC, an individualized, multidisciplinary management strategy is essential. Increased awareness of such mixed neoplasms may enhance diagnostic precision and improve patient care.

## Linked entities

- **Proteins:** shg (shotgun), RPE65 (retinoid isomerohydrolase RPE65), KIT (KIT proto-oncogene, receptor tyrosine kinase), Mki67 (antigen identified by monoclonal antibody Ki 67)
- **Diseases:** adenoid cystic carcinoma (MONDO:0004971), invasive lobular carcinoma (MONDO:0005051), triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, FOXA1 [NCBI Gene 107315065], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, MYH11 (myosin heavy chain 11) [NCBI Gene 4629] {aka AAT4, FAA4, SMHC, SMMHC, SMMS-1, VSCM2}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602] {aka Cmyb, c-myb, c-myb_CDS, efg}, TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}, PTEN [NCBI Gene 107315619], S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, FOXA1 (forkhead box A1) [NCBI Gene 3169] {aka HNF3A, TCF3A}, PIK3CA [NCBI Gene 107318114], PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, NFIB (nuclear factor I B) [NCBI Gene 4781] {aka CTF, HMGIC/NFIB, MACID, NF-I/B, NF1-B, NFI-B}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}
- **Diseases:** Invasive (MESH:D009361), triple-negative breast cancer (MESH:D064726), Adenoid Cystic and Lobular Carcinoma of the Breast (MESH:D001943), ductal carcinoma (MESH:D044584), ILC (MESH:D018275), atrial fibrillation (MESH:D001281), Classic-type lobular carcinoma in situ (MESH:D000071960), atrophic breast (MESH:D061325), metastasis (MESH:D009362), ulcerative esophagitis (MESH:D004941), ACCs (MESH:D058540), benign (MESH:D009369), pain (MESH:D010146), Breast ACC (MESH:D005348), ACC (MESH:D003528)
- **Chemicals:** anastrozole (MESH:D000077384), paraffin (MESH:D010232)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12917435/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12917435/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12917435/full.md

---
Source: https://tomesphere.com/paper/PMC12917435